Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
M Elaine Husni, Eunice Chang, Michael S Broder, Caleb Paydar, Katalin Bognar, Pooja Desai, Yuri Klyachkin & Ibrahim Khilfeh. (2022) Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database. Open Access Rheumatology: Research and Reviews 14, pages 123-132.
Read now
Read now
Articles from other publishers (16)
Lina M. Saldarriaga-Rivera, Wilson Bautista-Molano, Alejandro Junca-Ramírez, Andrés R. Fernández-Aldana, Daniel G. Fernández-Ávila, Diego A. Jaimes, Edwin A. Jáuregui, Juan S. Segura-Charry, Consuelo Romero-Sánchez & Oscar J. Felipe-Diaz. (2022) 2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology. Reumatología Clínica (English Edition) 18:1, pages 5-14.
Crossref
Crossref
Lina M. Saldarriaga-Rivera, Wilson Bautista-Molano, Alejandro Junca-Ramírez, Andrés R. Fernández-Aldana, Daniel G. Fernández-Ávila, Diego A. Jaimes, Edwin A. Jáuregui, Juan S. Segura-Charry, Consuelo Romero-Sánchez & Oscar J. Felipe-Diaz. (2022) Guía de práctica clínica 2021 para el diagnóstico, el tratamiento y el seguimiento de pacientes con espondiloartritis periférica. Asociación Colombiana de Reumatología. Reumatología Clínica 18:1, pages 5-14.
Crossref
Crossref
Lina M. Saldarriaga-Rivera, Wilson Bautista-Molano, Alejandro Junca-Ramírez, Andrés R. Fernández-Aldana, Daniel G. Fernández-Ávila, Diego A. Jaimes, Edwin A. Jáuregui, Juan S. Segura-Charry, Consuelo Romero-Sánchez & Oscar J. Felipe-Diaz. (2022) 2021 clinical practice guidelines for the diagnosis, treatment, and follow-up of patients with peripheral spondyloarthritis. Colombian Association of Rheumatology. Revista Colombiana de Reumatología (English Edition) 29:1, pages 44-56.
Crossref
Crossref
Lina M. Saldarriaga-Rivera, Wilson Bautista-Molano, Alejandro Junca-Ramírez, Andrés R. Fernández-Aldana, Daniel G. Fernández-Ávila, Diego A. Jaimes, Edwin A. Jáuregui, Juan S. Segura-Charry, Consuelo Romero-Sánchez & Oscar J. Felipe-Diaz. (2022) Guía de práctica clínica 2021 para el diagnóstico, el tratamiento y el seguimiento de pacientes con espondiloartritis periférica. Asociación Colombiana de Reumatología. Revista Colombiana de Reumatología 29:1, pages 44-56.
Crossref
Crossref
Vijay K. Sandhu, Lihi Eder & Jensen Yeung. (2020) Apremilast and its role in psoriatic arthritis. Giornale Italiano di Dermatologia e Venereologia 155:4.
Crossref
Crossref
Jashin J. Wu, Corey Pelletier, Brian Ung, Marc Tian, Ibrahim Khilfeh & Jeffrey R. Curtis. (2020) Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis. Advances in Therapy 37:5, pages 2098-2115.
Crossref
Crossref
Koichi Ando, Akihiko Tanaka & Hironori Sagara. (2020) Comparative Efficacy and Safety of Dupilumab and Benralizumab in Patients with Inadequately Controlled Asthma: A Systematic Review. International Journal of Molecular Sciences 21:3, pages 889.
Crossref
Crossref
Gabriel Tremblay, Tracy Westley, Anna Forsythe, Corey Pelletier & Andrew Briggs. (2019) A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. Journal of Comparative Effectiveness Research 8:15, pages 1265-1298.
Crossref
Crossref
Karen Smith, Su Golder, Abeed Sarker, Yoon Loke, Karen O’Connor & Graciela Gonzalez-Hernandez. (2018) Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. Drug Safety 41:12, pages 1397-1410.
Crossref
Crossref
Iain B McInnes, Peter Nash, Christopher Ritchlin, Ernest H Choy, Steve Kanters, Howard Thom, Kunal Gandhi, Luminita Pricop & Steffen M Jugl. (2018) Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. Journal of Comparative Effectiveness Research 7:11, pages 1107-1123.
Crossref
Crossref
Karon F. Cook, Michael A. Kallen, Cheryl D. Coon, David Victorson & Deborah M. Miller. (2017) Idio Scale Judgment: evaluation of a new method for estimating responder thresholds. Quality of Life Research 26:11, pages 2961-2971.
Crossref
Crossref
Emma D. Deeks, Katherine A. Lyseng-Williamson & Gillian M. Keating. (2017) Apremilast in psoriasis: a profile of its use. Drugs & Therapy Perspectives 33:8, pages 361-367.
Crossref
Crossref
Gillian M. Keating. (2017) Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs 77:4, pages 459-472.
Crossref
Crossref
Michael Reed & David Crosbie. (2017) Apremilast in the treatment of psoriatic arthritis: a perspective review. Therapeutic Advances in Musculoskeletal Disease 9:2, pages 45-53.
Crossref
Crossref
Vibeke Strand, Elaine Husni, Jenny Griffith, Zheng-Yi Zhou, James Signorovitch & Arijit Ganguli. (2016) Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. Rheumatology and Therapy 3:2, pages 305-322.
Crossref
Crossref
April W. Armstrong, Keith A. Betts, Murali Sundaram, Darren Thomason & James E. Signorovitch. (2016) Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis. Journal of the American Academy of Dermatology 75:4, pages 740-746.
Crossref
Crossref